Cancer is, after heart disease, the second most common cause of death in the developed countries nowadays. Cancer stem cells (CSCs) are cancer cells (found within tumors) that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample.
A Spanish research group from the public health service, whose field of activity is, among others, medical oncology, supported by two universities, has developed a cell culture medium for isolating and/or enriching cancer stem cells, produced by culturing of mesenchymal stem cells in a conventional serum-free medium.
The patented technology consists in sowing, in the previous conditioned medium, a sample containing CSCs, and producing the cell population, with the additional characteristic that, before culturing the CSCs in the conditional medium, the culture is treated with diluted trypsin, and the cells, which are sensitive to trypsin and have a higher percentage of CSCs, are isolated.
The technology is serum free, which promotes the in vitro proliferation and conservation of pluripotency potential which allows to maintain an undifferentiated state of cancer stem cells subpopulation and at the same time does not allow the survival of differentiated cells.
The group is looking for the following collaboration:
-License agreement, in the framework of authorizing the interested parties to use the technology.
-Technical cooperation agreement, to collaborate with other research teams, companies or foundations.